항진균제 : 시장 인사이트, 경쟁 구도, 시장 예측(2030년)

Antifungal Drugs Market by Indication (Aspergillosis, Dermatophytosis, Candidiasis, and Others), Drug Type (Echinocandins [Caspofungin, Micafungin, and Others], Azoles [Voriconazole, Posaconazole, Clotrimazole, and Others], Polyenes [Amphotericin and Others], Allylamines [Terbinafine and Others], and Others), Dosage Form (Powder, Ointments, Tablets, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of fungal infections and the increasing research & developmental activities on antifungal drugs across the globe

The antifungal drugs market was valued at USD 14,636.88 million in 2023 and is likely to register a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 19,162.67 million by 2030. The antifungal drugs market is observing substantial market growth owing to the growing prevalence of various fungal infections such as fungal nail infections, ringworm, vaginal candidiasis, aspergillosis, candida infections of mouth, throat, and esophagus, fungal eye infections, and others. The increasing research & developmental activities such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, availability of antifungal drugs as over-the-counter (OTC), surging demand for generic antifungal drugs, and others will aid in driving the market for antifungal drugs during the forecast period from 2024 to 2030.

Antifungal Drugs Market Dynamics:

According to a recent study done by Global Action for Fungal Infections, globally over 80 million people are at risk of serious fungal infection yearly. Moreover, as per the same source, invasive aspergillosis affects nearly 2,100,000 people, and invasive candidiasis affects nearly 1,565,000 people yearly, worldwide.

The growing prevalence of nosocomial or hospital-acquired infections will aid in propelling the market of antifungal drugs during the forecast period. The World Health Organization (WHO) in 2022 stated that in high-income countries, approximately 24% of the patients in intensive care units are affected by at least 1 healthcare-associated infection. Whereas, in middle to low income countries the frequency of intensive care acquired infection is 52.3% which is 2-3 times higher than that of high-income countries. Thus, the increasing prevalence of hospital acquired infections is anticipated to propel the demand for antifungal drugs.

Additionally, the increasing awareness of fungal infections, surging number of over-the-counter antifungal (OTC) drugs, and the increased use of antifungal drugs in developing countries, and others will contribute to the growth of the antifungal drugs market. Also, there is a growing popularity of over-the-counter (OTC) drugs such as clotrimazole, econazole, ketoconazole, miconazole, and amorolfine, that experience high market demand.

Moreover, the increased product developmental activities in antifungal drugs are expected to push forward the market growth. For instance, in May 2022, Shionogi & Co., Ltd. and F2G Ltd. announced the collaboration to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in Europe and Asia. It is a novel oral antifungal therapy developed by F2G for the treatment of invasive aspergillosis (IA) and other rare mold infections.

Also, in October 2021, Intas Pharmaceuticals Limited announced the launch of an innovative antifungal drug, Super Bioavailable Itraconazole-SB 100mg under the brand name - Itaspor-SB Forte/Subawin. The drug substantially reduced the cost of the therapy for fungal infection, improve patient compliance, and reduce the doctor's counseling time.

Therefore, all the factors mentioned above will collectively drive the overall antifungal drugs market throughout the forecast period from 2024 to 2030.

However, the increasing resistance to antifungal drugs, their side effects, and the stringent regulatory approval process may halt the market growth of antifungal drugs.

Antifungal Drugs Market Segment Analysis:

Antifungal Drugs Market by Indication (Aspergillosis, Dermatophytosis, Candidiasis, and Others), Drug Type (Echinocandins [Caspofungin, Micafungin, and Others], Azoles [Voriconazole, Posaconazole, Clotrimazole, and Others], Polyenes [Amphotericin and Others], Allylamines [Terbinafine and Others], and Others), Dosage Form (Powder, Ointments, Tablets, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug type segment of the antifungal drugs market, the clotrimazole category is expected to have a significant revenue share in the year 2023. This is primarily owing to the increasing prevalence of fungal infections across the globe, expanding launches, strategic investments, and other activities by key players related to the segment thus driving its market during the forecast period. Further, the wide application circle of clotrimazole is anticipated to propel its market during the forecast period.

For example, azoles drugs are used to treat thrush, yeast infection, candidiasis, aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, fungal infections, systemic mycosis, and seborrheic dermatitis. Also, clotrimazole provides a broad spectrum of activity and improved safety standards. The medication has fewer side effects and improved absorption and distribution properties.

Further, various other strategic steps taken by key players in the market will help in increasing the demand for antifungals. For instance, in December 2022, Salvat Laboratory submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for Clotrimazole, an innovative pharmaceutical agent for the treatment of otomycosis. This novel drug became the sole product available in both the United States and Europe specifically designed and indicated for the topical management of fungal otitis externa.

Also, in June 2021, Cadila Pharmaceuticals launched a new triazole antifungal drug Posaconazole that is effective against a wide range of invasive fungal diseases. The drug was also recommended as a second-line treatment for Mucormycosis.

Therefore, owing to the above-mentioned factors, the demand for azoles is expected to rise, owing to which the category is expected to witness considerable growth eventually contributing to the overall growth of the antifungal drugs market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall antifungal drugs market:

Among all the regions, North America is expected to dominate the antifungal drugs market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This can be ascribed to the increasing demand for antifungal drugs among patients in the region owing to the increasing prevalence of various fungal infections such as athlete's foot, jock itch, ringworm, Aspergillosis, Candidiasis, and others. Further, the increasing number of antifungal drugs as over-the-counter (OTC), the rising awareness about the treatment of fungal infections, and the presence of key domicile players contribute to the growth of the antifungal drugs market in North America during the forecast period from 2024 to 2030.

According to the Centers for Disease Control and Prevention (CDC) 2022, an estimated 1.4 million outpatient visits for vaginal candidiasis occur annually, in the US. Additionally, as per the same source, resistance to certain strains of Candida (which occurs as a common cause of blood-related infections in the US) had been noted in the US and about 7% of all Candida bloodstream tests were not resistant to fluconazole.

Furthermore, various players are conducting clinical trials on antifungal drugs, which will create an opportunity for the market to grow in the upcoming years. For instance, Scynexis, Inc., the US-based biotech company, is conducting a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy and safety of ibrexafungerp in patients >= 18 years of age with a documented invasive and/or severe fungal disease that had been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

Also, the market players in the country are continuously concentrating on the development of novel drugs to tackle fungal infections using antifungal drugs, and they are also adopting various strategies to develop better drugs with reduced side effects. For instance, in May 2022, the US Food and Drug Administration approved Vivjoa (oteseconazole) by Mycovia Pharmaceuticals' azole antifungal for chronic vaginal yeast infection. Oteseconazole, a tetrazole, is designed to inhibit fungal CYP51 enzymes but not human CYP enzymes. Human enzyme inhibition accounts for the side effects of other azole antifungals, thus reducing the side effects.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North America region in the antifungal drugs market.

Antifungal Drugs Market Key Players:

Some of the key market players operating in the Antifungal Drugs market include Abbott Bayer AG, GSK plc, Merck & Co., Inc, Cadila Pharmaceuticals, Glenmark, SCYNEXIS, Inc, Astellas Pharma d.o.o, Arcadia Consumer Healthcare, Novartis AG, Pfizer Inc, Leadiant Biosciences, Inc, Sun Pharmaceutical Industries Ltd, Viatris Inc, Sanofi, Gilead Sciences, Inc, Apotex Inc, Aurobindo Pharma USA, Cipla Inc, Dr. Reddy's Laboratories Ltd, and others.

Recent Developmental Activities in the Antifungal Drugs Market:

• In March2023, the US Food and Drug Administration (FDA) approved Cidara's New Drug Application (NDA) for rezafungin injection to treat candidaemia and invasive candidiasis (C/IC) in patients 18 years of age or older who have limited or no alternative treatment options.
• In May 2022 announced the launch of the new and improved range of Canesten, their anti-fungal treatment solution in India.
• In June 2021, Scynexis announced the approval of Brexafemme by the United States Food and Drug Administration for the treatment of vaginal yeast infections.

Key Takeaways from the Antifungal Drugs Market Report Study

• Market size analysis for current antifungal drugs market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the antifungal drugs market.
• Various opportunities available for the other competitors in the antifungal drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current antifungal drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antifungal drugs market growth in the coming future?

Target audience who can be benefited from this Antifungal Drugs Market Report Study

• Antifungal drugs providers
• Research organizations and consulting companies
• Antifungal drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in antifungal drugs
• Various end-users who want to know more about the antifungal drugs market and the latest developments in the antifungal drugs market.

Frequently Asked Questions for the Antifungal Drugs Market:

1. What are Antifungal Drugs?

Antifungal drugs are prescribed to treat diseases caused by various fungi such as Aspergillosis, candida, and others. These drugs work either by killing the fungal cells or stopping them from growing and multiplying. Antifungal drugs can be administered orally, applied topically, or intravenously through an IV drip.

2. What is the market for Antifungal Drugs?

The antifungal drugs market was valued at USD 14,636.88 million in 2023 and is likely to register a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 19,162.67 million by 2030.

3. What are the drivers for the Antifungal Drugs market?

The antifungal drugs market is experiencing significant growth, driven by factors such as the growing prevalence of various fungal infections, the increasing number of antifungal drugs as over-the-counter (OTC), the surging incidence of nosocomial infections worldwide, increasing product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, surging new drug launches and approvals, presence of key players in the market, and others will create an exigency for the antifungal drugs market. Therefore, the market for antifungal drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

4. Who are the key players operating in the antifungal drugs market?

Some of the key market players operating in the Antifungal Drugs market include Abbott Bayer AG, GSK plc, Merck & Co., Inc, Cadila Pharmaceuticals, Glenmark, SCYNEXIS, Inc, Astellas Pharma d.o.o, Arcadia Consumer Healthcare, Novartis AG, Pfizer Inc, Leadiant Biosciences, Inc, Sun Pharmaceutical Industries Ltd, Viatris Inc, Sanofi, Gilead Sciences, Inc, Apotex Inc, Aurobindo Pharma USA, Cipla Inc, Dr. Reddy's Laboratories Ltd, and others.

5. Which region has the highest share in the antifungal drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the antifungal drugs market. This can be ascribed to the increasing demand for antifungal drugs among the patients in the region owing to the increasing prevalence of various fungal infections such as athlete's foot, jock itch, ringworm, Aspergillosis, Candidiasis, and others. Further, the increasing number of antifungal drugs as over-the-counter (OTC), the rising awareness about the treatment of fungal infections, and the presence of key domicile players in the region are the reasons that act as a supportive factor for the North American antifungal drugs market growth during the forecast period from 2024 to 2030.

Table of Contents

1. Antifungal Drugs Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Antifungal Drugs Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Antifungal Drugs Market Key Factors Analysis

• 5.1. Antifungal Drugs Market Drivers
  • 5.1.1. Growing prevalence of various fungal infections
  • 5.1.2. Increasing number of antifungal drugs as over-the-counter (OTC) drugs
  • 5.1.3. Increasing product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections
• 5.2. Antifungal Drugs Market Restraints and Challenges
  • 5.2.1. Increasing resistance to antifungal drugs
  • 5.2.2. Side effects of antifungal drugs
  • 5.2.3. Stringent regulatory approvals
• 5.3. Antifungal Drugs Market Opportunities
  • 5.3.1. Availability of a robust product portfolio of antifungal drugs in various emerging countries

6. Antifungal Drugs Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Antifungal Drugs Market Assessment

• 7.1. By Indication
  • 7.1.1. Aspergillosis
  • 7.1.2. Dermatophytosis
  • 7.1.3. Candidiasis
  • 7.1.4. Others
• 7.2. By Drug Type
  • 7.2.1. Echinocandins
    • 7.2.1.1. Caspofungin
    • 7.2.1.2. Micafungin
    • 7.2.1.3. Others
  • 7.2.2. Azoles
    • 7.2.2.1. Voriconazole
    • 7.2.2.2. Posaconazole
    • 7.2.2.3. Clotrimazole
    • 7.2.2.4. Others
  • 7.2.3. Polyenes
    • 7.2.3.1. Amphotericin (AmBisome)
    • 7.2.3.2. Others
  • 7.2.4. Allylamines
    • 7.2.4.1 Terbinafine
    • 7.2.4.2 Others
• 7.3. By Dosage Form
  • 7.3.1. Powder
  • 7.3.2. Ointments
  • 7.3.3. Tablets
  • 7.3.4. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.1.2. Canada Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.1.3. Mexico Antifungal Drugs Market Size in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.2.2. Germany Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.2.4. Italy Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.2.5. Spain Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Antifungal Drugs Market Size in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.3.2. Japan Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.3.3. India Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.3.4. Australia Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.3.5. South Korea Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Antifungal Drugs Market Size in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.4.2. Africa Antifungal Drugs Market Size in USD million (2021-2030)
    • 7.4.4.3. South America Antifungal Drugs Market Size in USD million (2021-2030)

8. Antifungal Drugs Market Company and Product Profiles

• 8.1. Abbott
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Bayer AG
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. GSK plc
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Merck & Co., Inc
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Cadila Pharmaceuticals
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Glenmark
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. SCYNEXIS, Inc
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Astellas Pharma d.o.o
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Arcadia Consumer Healthcare
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Novartis AG
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Pfizer Inc
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Leadiant Biosciences, Inc
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Sun Pharmaceutical Industries Ltd
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Viatris Inc
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Sanofi
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Gilead Sciences, Inc
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Apotex Inc
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Aurobindo Pharma USA
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Cipla Inc
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Dr. Reddy's Laboratories Ltd
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us